Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: Results from the PRECISION V randomized trial

American Journal of Roentgenology

Volumn 197, Issue 4, 2011, Pages

  Vogl, Thomas J ^a   Lammer, Johannes ^b   Lencioni, Riccardo ^c   Malagari, Katerina ^d   Watkinson, Anthony ^e   Pilleul, Frank ^f   Denys, Alban ^g   Lee, Clara ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c CISANELLO HOSPITAL   (Italy)

^d UNIVERSITY OF ATHENS   (Greece)

^e ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^f HOSPICES CIVILS DE LYON   (France)

^g LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Doxorubicin; Drug eluting bead embolization; Hepatocellular carcinoma (HCC); Toxicity; Transarterial chemoembolization (TACE)

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DOXORUBICIN; GELATIN SPONGE; IODINATED POPPYSEED OIL; IOHEXOL; IOMEPROL; IOMEROL; IOPAMIDOL; MICROSPHERE; POLYVINYL ALCOHOL; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER STAGING; CARDIOTOXICITY; CHEMOEMBOLIZATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ELUTING BEAD; DRUG FEVER; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HEART LEFT VENTRICLE EJECTION FRACTION; HEPATOBILIARY DISEASE; HEPATOBILIARY SYSTEM; HUMAN; INFECTION; INFESTATION; LABORATORY TEST; LIVER CELL CARCINOMA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PARTICLE SIZE; POSTEMBOLIZATION SYNDROME; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; SINGLE BLIND PROCEDURE; UPPER ABDOMINAL PAIN; VOMITING;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CHI-SQUARE DISTRIBUTION; DOXORUBICIN; DRUG-INDUCED LIVER INJURY; ECHOCARDIOGRAPHY; FEMALE; GASTROINTESTINAL DISEASES; HEART DISEASES; HUMANS; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MICROSPHERES; PROGNOSIS; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 80053274492     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.10.4379     Document Type: Article

References (33)

1. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127[suppl 1]:S5-S16 (Pubitemid 39423365)
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-249
3. Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol 2007; 4:424-432 (Pubitemid 47039693)
4. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42:1208-1236 (Pubitemid 43112690)
5. González HD, Figueras J. Surgical treatment for hepatocellular carcinoma in cirrhotic patients: guide to the selection and decision-making process in a context of multimodal strategy. Clin Transl Oncol 2009; 11:20-27
6. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37:429-442 (Pubitemid 36152543)
7. Llovet JM, Real MI, Montaña X, et al Barcelona Liver Cancer Group. Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 2002; 359:1734-1739 (Pubitemid 34607087)
8. Llovet JM, Fuster J, Bruix J; Barcelona-Clínic Liver Cancer Group. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004; 10[suppl 1]:S115-S120 (Pubitemid 38240111)
9. Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30:6-25 (Pubitemid 44900485)
10. Matsuo N, Uchida H, Sakaguchi H, et al. Optimal Lipiodol volume in transcatheter arterial chemoembolotherapy for hepatocellular carcinoma: study based on Lipiodol accumulation patterns and histopathologic findings. Semin Oncol 1997; 24[2 suppl 6]:S6-61-S6-70
11. Malagari K, Alexopoulou E, Chatzimichail K, et al. Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC Bead. Abdom Imaging 2008; 33:512-519
12. Lewis AL, Taylor RR, Hall B, Gonzalez MV, Willis SL, Stratford PW. Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization. J Vasc Interv Radiol 2006; 17:1335-1343 (Pubitemid 44259017)
13. Lewis AL, Gonzalez MV, Lloyd AW, et al. DC Bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 2006; 17:335-342 (Pubitemid 44341453)
14. Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46:474-481 (Pubitemid 46201723)
15. Lammer J, Malagari K, Vogl TJ, et al. Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: results of the PRECISION V Study. Cardiovasc Intervent Radiol 2010; 33:41-52
16. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Lancet 2001; 357:1191-1194 (Pubitemid 32378696)
17. Bruix J, Sherman M, Llovet JM, et al EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35:421-430 (Pubitemid 32844200)
18. Coltman CA Jr; Southwest Oncology Group. The Southwest Oncology Group: progress in cancer research. Semin Oncol 2008; 35:545-552
19. Maleux G, van Malenstein H, vandecaveye V, et al. Transcatheter chemoembolization of unresectable hepatocellular carcinoma: current knowledge and future directions. Dig Dis 2009; 27:157-163
20. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48[suppl 1]:S20-S37
21. Cammà C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002; 224:47-54 (Pubitemid 34680374)
22. Kirchhoff TD, Bleck JS, Dettmer A, et al. Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival. Hepatobiliary Pancreat Dis Int 2007; 6:259-266 (Pubitemid 46925246)
23. Verslype C, van Cutsem E, Dicato M, et al. The management of hepatocellular carcinoma: current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. Ann Oncol 2009; 20[suppl 7]:vii1-vii6
24. Lencioni R, Malagari K, Vogl TJ, et al. A randomized phase II trial of drug-eluting beads in the treatment of HCC by transarterial chemoembolization. (abstr) American Society of Clinical Oncology Website. www.asco.org GI Cancer Symposium 2009; abstract 116. Accessed January 12, 2011
25. Kettenbach J, Stadler A, Katzler IV, et al. Drugloaded microspheres for the treatment of liver cancer: review of current results. Cardiovasc Intervent Radiol 2008; 31:468-476
26. Grosso M, Vignali C, Quaretti P, et al. Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres: preliminary results from an Italian multicentre study. Cardiovasc Intervent Radiol 2008; 31:1141-1149
27. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial Lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35:1164-1171 (Pubitemid 34454013)
28. Buijs M, Vossen JA, Frangakis C, et al. Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoemboliza tion - single-center experience. Radiology 2008; 249:346-354
29. Chan AO, Yuen MF, Hui CK, Tso WK, Lai CL. A prospective study regarding the complications of transcatheter intraarterial Lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 2002; 94:1747-1752 (Pubitemid 34241113)
30. Sacco R, Bertini M, Petruzzi P, et al. Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: a cohort study. World J Gastroenterol 2009; 15:1843-1848
31. Poon RT, Tso WK, Pang RW, et al. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 2007; 5:1100-1108
32. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004; 127[suppl 1]:S179-S188 (Pubitemid 39423386)
33. National Cancer Institute Website. Drug information: FDA approval for sorafenib tosylate - Nexavar prescribing information. www.cancer.gov/ cancertopics/druginfo/fda-sorafenib-tosylate. Published December 20, 2005. Updated November 19, 2007. Accessed January 12, 2011